TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06049433

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention
Description: The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
Study: NCT06047366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine w/ epi
Description: Septodont's standard formulation of 4% articaine with epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine plain
Description: Septodont's standard formulation of 3% mepivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine plain
Description: Septodont's standard formulation of 3% mepivacaine
Study: NCT06025396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP-301
Description: Multiple ascending dose active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple ascending dose comparator
Study: NCT05787977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Feedback and Rhythmic Auditory Cue
Description: Patients were trained five times per week for eight weeks. After eight weeks of training the gait pattern and balance was evaluated by the gait parameters, 6min Walk test, Pediatric Balance Scale and Berg balance scale.
Study: NCT04141995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Tablet, Oral: Generic: 0.125 mg, 0.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 5-FU will be given as a 46 hour continuous IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Leucovorin
Description: IV injection over 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV administration over 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV administration
Study: NCT06225778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6-week online exercise group
Study: NCT05482087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: ALK inhibitor-treated ALK-positive NSCLC treatment
Study: NCT05852587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered by the BWH investigational drug services. The placebo will be composed of cellulose microcrystal.
Study: NCT05329415

Intervention type: DIAGNOSTIC_TEST
Intervention: TB Drug Levels
Description: TB drug levels at 1-2 time points at weeks 2, 8 and 16

Intervention type: DIAGNOSTIC_TEST
Intervention: TB Drug Levels
Description: TB drug levels at 1-2 time points at weeks 2, 8 and 16
Study: NCT05974345

Intervention type: DRUG
Intervention: Inclisiran sodium
Description: Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.

Intervention type: DRUG
Intervention: Placebo
Description: Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.

Intervention type: DRUG
Intervention: Ezetimibe
Description: Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.

Intervention type: DRUG
Intervention: Evolocumab
Description: Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.
Study: NCT06049433

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention
Description: The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention
Description: The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
Study: NCT04777682

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound, double balloon enteroscopy
Description: compare intestinal ultrasound versus double-balloon enteroscopy in diagnosis of malabsorption syndrome
Study: NCT06049433

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: On-Demand + Discussion board (DB)
Description: Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. a discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Arm 2
Description: The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. On-demand multi-media MBCT content (digital audio-video files and downloadable content)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: On Demand (OD) + Video Conference (VC)
Description: on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. A discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Arm 3
Description: The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings.
Study: NCT05637606

Intervention type: DRUG
Group type: OTHER
Intervention: Ephedrine
Description: In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started

Intervention type: DRUG
Group type: OTHER
Intervention: Norepinephrine
Description: In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.

Intervention type: DRUG
Group type: OTHER
Intervention: Etilefrine Hydrochloride bolus
Description: The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etilefrine Hydrochloride bolus
Description: The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)
Description: PPV, SVV and mini_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)
Description: PPV, SVV and mini_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery
Study: NCT05660265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4172239D
Description: Different strength of GSK4172239D will be administered in different cohorts.
Study: NCT06049433

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: On Demand (OD) + Video Conference (VC)
Description: Access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC)
Study: NCT05908149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole Splint
Description: Insole splint used in 'Pes equinus' in patients with hemiplegia
Study: NCT05961228

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: Three different posture with and without correction according to the Schroth method
Study: NCT05959018

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Arrow Three-Lumen Central Venous Catheter
Description: Participants in the Non-impregnated CVC arm will receive Arrow Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter
Description: Participants in the Antimicrobial-impregnated CVC arm will receive Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
Study: NCT06393712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-APP
Description: ALN-APP will be administered intrathecally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALN-APP
Description: ALN-APP will be administered intrathecally
Study: NCT05878522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sisunatovir
Description: 6 capsules administered Q12 hours for 5 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 capsules administered Q12 hours for 5 doses
Study: NCT05759169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Bath Tub
Description: A foot bath is generally a form of rest and care where feet are put in water. Feet are body areas where fatigue is most felt as organs that carry the body's total weight. This study uses a specially designed foot bath bath bath bath to give the patients in the experimental group foot bath. The cuvette has four-stage water heating (35-45°C). It has a magnetic field and operates at 390 Watts. It has a splash guard. The sole features non-slip rubber feet. It has a heat shield feature because it has a double wall construction for heat isolation.
Study: NCT05294770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optisource® Plus: Very Low Calorie Diet treatment
Description: Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric Mediterranean Diet
Description: Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (\<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
Study: NCT04716400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop sexual harassment
Description: Teachers will be introduced to a digital course on the prevention of sexual- and gendered harassment. In the course they will provided with a manual containing eight lessons to be held for the pupils. Each lesson will last 45 minutes and consist of a short lecture and practical activities for the pupils.
Study: NCT06424925

Intervention type: OTHER
Intervention: Artificial intelligence for the prediction of clinical outcomes
Description: Use of artificial intelligence (AI) for the prediction of clinical outcomes such as death and complications in patients hospitalized for COVID pneumonia during the 4 pandemic waves

Intervention type: OTHER
Intervention: Artificial intelligence for the prediction of clinical outcomes
Description: Use of artificial intelligence (AI) for the prediction of clinical outcomes such as death and complications in patients hospitalized for COVID pneumonia during the 4 pandemic waves

Intervention type: OTHER
Intervention: Artificial intelligence for the prediction of clinical outcomes
Description: Use of artificial intelligence (AI) for the prediction of clinical outcomes such as death and complications in patients hospitalized for COVID pneumonia during the 4 pandemic waves

Intervention type: OTHER
Intervention: Artificial intelligence for the prediction of clinical outcomes
Description: Use of artificial intelligence (AI) for the prediction of clinical outcomes such as death and complications in patients hospitalized for COVID pneumonia during the 4 pandemic waves
Study: NCT05164848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
Study: NCT05660265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4172239D
Description: Different strength of GSK4172239D will be administered in different cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4172239D
Description: Different strength of GSK4172239D will be administered in different cohorts.
Study: NCT05878522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sisunatovir
Description: 7 capsules administered Q12 hours for 5 doses
Study: NCT06057532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UCAN SuperStarch
Description: Intervention patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the intervention study drink and record information about how they feel before and after consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gatorade
Description: Active control patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the active control study drink and record information about how they feel before and after consumption.
Study: NCT06394193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based participatory research intervention
Description: Two training sessions (roughly two hours each) to train them in the intervention structure and curriculum
Study: NCT05660265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4172239D
Description: Different strength of GSK4172239D will be administered in different cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4172239D
Description: Different strength of GSK4172239D will be administered in different cohorts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study: NCT05699434

Intervention type: BEHAVIORAL
Intervention: Obstetrics and Gynecology residents and experts'
Description: Obstetrics and Gynecology residents and experts' knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey (Istanbul)
Study: NCT04846608

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT05164848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
Study: NCT06189352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive feeding of the preterm infant
Description: Feeding strategy for the preterm infant with description of nutritional needs and based on the infants development and cues.
Study: NCT05897762

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tele rehabilitation Group
Description: It has been determined that the telerehabilitation method applied in chronic hemiplegic patients increases daily living activities, upper extremity functionality, and spasticity levels decrease.
Study: NCT06157333

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)
Description: The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device available in our center was used.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)
Description: The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device available in our center was used.
Study: NCT06545526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib monotherapy
Description: Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib and metformin combination
Description: Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
Study: NCT04643782

Intervention type: DEVICE
Group type: OTHER
Intervention: ANNE Sleep
Description: ANNE sleep system
Study: NCT04831125

Intervention type: OTHER
Intervention: Data collection
Description: Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.